[开放获取]    人干扰素α1b治疗黑色素瘤专家共识（2024版）

doi:10.35541/cjd.20230317

Abstract

Abstract: 【Abstract】 Human interferon α1b is the first genetically engineered classⅠ drug in China, and has been approved for the treatment of melanoma and other tumors. As an adjuvant treatment for resected melanoma and a systemic treatment for advanced melanoma, human interferon α1b can effectively improve the survival of patients while maintaining a favorable safety profile. Based on clinical application experience and recent literature, the Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine and Melanoma Society of China Anti-Cancer Association convened experts in this field to develop this consensus, aiming to provide a reference for clinical treatment decisions regarding melanoma.

Key words: Melanoma, Interferon-alpha, Antineoplastic protocols, Postoperative adjuvant therapy, Human interferon α1b, Systemic therapy, Expert consensus

Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Melanoma Society of China Anti-Cancer Association. Expert consensus on human interferon α1b for the treatment of melanoma （2024）[J]. Chinese Journal of Dermatology, 2024, 57(1): 1-7.doi:10.35541/cjd.20230317

References ［49］

［1］	Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040［J］. JAMA Dermatol, 2022,158（5）:495⁃503. doi: 10.1001/jamadermatol.2022. 0160.
［2］	Wu Y, Wang Y, Wang L, et al. Burden of melanoma in China, 1990 -2017: findings from the 2017 global burden of disease study［J］. Int J Cancer, 2020,147（3）:692⁃701. doi: 10.1002/ijc.32764.
［3］	Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases［J］. BMC Cancer, 2011,11:85. doi: 10.1186/1471⁃2407⁃11⁃85.
［4］	Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma［J］. Surg Oncol Clin N Am, 2011,20（1）:1⁃17. doi: 10.1016/j.soc.2010.09.007.
［5］	Newell F, Kong Y, Wilmott JS, et al. Whole⁃genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets［J］. Nat Commun, 2019,10（1）:3163. doi: 10.1038/s41467⁃ 019⁃11107⁃x.
［6］	Farshidfar F, Rhrissorrakrai K, Levovitz C, et al. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis［J］. Nat Commun, 2022,13（1）:898. doi: 10.1038/s41467⁃022⁃28566⁃4.
［7］	Shi Q, Liu L, Chen J, et al. Integrative genomic profiling uncovers therapeutic targets of acral melanoma in Asian populations［J］. Clin Cancer Res, 2022,28（12）:2690⁃2703. doi: 10.1158/1078⁃0432.CCR⁃21⁃3344.
［8］	Tang B, Chi Z, Chen Y, et al. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS⁃01 multicenter phaseⅡ trial［J］. Clin Cancer Res, 2020,26（16）:4250⁃4259. doi: 10. 1158/1078⁃0432.CCR⁃19⁃3922.
［9］	Si L, Zhang X, Shu Y, et al. A phase Ib study of pembrolizumab as second⁃line therapy for Chinese patients with advanced or metastatic melanoma （KEYNOTE⁃151）［J］. Transl Oncol, 2019,12（6）:828⁃835. doi: 10.1016/j.tranon.2019.02.007.
［10］	Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa⁃2b adjuvant therapy of high⁃risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684［J］. J Clin Oncol, 2023,41（3）:425⁃435. doi: 10.1200/JCO. 22.02264.
［11］	Kirkwood JM, Ibrahim JG, Sondak VK, et al. High⁃ and low⁃dose interferon alfa⁃2b in high⁃risk melanoma: first analysis of intergroup trial E1690/S9111/C9190［J］. J Clin Oncol, 2000,18（12）:2444⁃2458. doi: 10.1200/JCO.2000.18.12.2444.
［12］	Kirkwood JM, Ibrahim JG, Sosman JA, et al. High⁃dose interferon alfa⁃2b significantly prolongs relapse⁃free and overall survival compared with the GM2⁃KLH/QS⁃21 vaccine in patients with resected stage ⅡB⁃Ⅲ melanoma: results of intergroup trial E1694/S9512/C509801［J］. J Clin Oncol, 2001,19（9）:2370⁃2380. doi: 10.1200/JCO.2001.19.9.2370.
［13］	Ives NJ, Suciu S, Eggermont A, et al. Adjuvant interferon⁃α for the treatment of high⁃risk melanoma: an individual patient data meta⁃analysis［J］. Eur J Cancer, 2017,82:171⁃183. doi: 10.1016/j.ejca.2017.06.006.
［14］	Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high⁃dose interferon alfa⁃2b therapy［J］. J Clin Oncol, 2002,20（17）:3703⁃3718. doi: 10.1200/JCO.2002.03.052.
［15］	Shi Q, Liu L, Zhang W, et al. Interferon⁃α1b for the treatment of metastatic melanoma: results of a retrospective study［J］. Anticancer Drugs, 2021,32（10）:1105⁃1110. doi: 10.1097/CAD. 0000000000001120.
［16］	Zhu G, Shi Q, Zhao B, et al. Efficacy and safety of interferon⁃alpha 1b combined with PD⁃1 monoclonal antibody in patients with unresectable stage Ⅳ melanoma: a retrospective study［J］. J Cancer Res Clin Oncol, 2023,149（9）:6263⁃6269. doi: 10. 1007/s00432⁃023⁃04596⁃3.
［17］	National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology for cutaneous: melanoma （version 3. 2023）［Z/OL］. ［2023⁃10⁃12］. https://www.nccn.org/guidelines/guidelines⁃detail?category=1&id=1492.
［18］	樊代明, 郭军. 中国肿瘤整合诊治指南黑色素瘤 2022［M］. 天津: 天津科学技术出版社, 2022:93.
［19］	Weissmann C, Nagata S, Boll W, et al. Structure and expression of human IFN⁃alpha genes［J］. Philos Trans R Soc Lond B Biol Sci, 1982,299（1094）:7⁃28. doi: 10.1098/rstb.1982.0102.
［20］	Pestka S. The human interferon⁃alpha species and hybrid proteins［J］. Semin Oncol, 1997,24（3 Suppl 9）:S9⁃4⁃S9⁃17.
［21］	侯云德, 张智清, 杨新科, 等. 人白细胞干扰素基因的克隆化及其在大肠杆菌中的表达［J］. 中国医学科学院学报, 1982（6）:327⁃335.
［22］	Zitvogel L, Galluzzi L, Kepp O, et al. TypeⅠinterferons in anticancer immunity［J］. Nat Rev Immunol, 2015,15（7）:405⁃414. doi: 10.1038/nri3845.
［23］	Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high⁃dose and low⁃dose interferon alpha2b in patients with high⁃risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690［J］. Cancer, 2002,95（5）:1101⁃1112. doi: 10.1002/cncr.10775.
［24］	Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon⁃alpha and granulocyte⁃macrophage colony⁃stimulating factor differentiate peripheral blood monocytes into potent antigen⁃presenting cells［J］. J Leukoc Biol, 1998,64（3）:358⁃367. doi: 10.1002/jlb.64.3. 358.
［25］	Papewalis C, Jacobs B, Wuttke M, et al. IFN⁃alpha skews monocytes into CD56+⁃expressing dendritic cells with potent functional activities in vitro and in vivo［J］. J Immunol, 2008,180（3）:1462⁃1470. doi: 10.4049/jimmunol.180.3.1462.
［26］	Parlato S, Santini SM, Lapenta C, et al. Expression of CCR⁃7, MIP⁃3beta, and Th⁃1 chemokines in typeⅠIFN⁃induced monocyte⁃derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities［J］. Blood, 2001,98（10）:3022⁃3029. doi: 10.1182/blood.v98.10.3022.
［27］	Brinkmann V, Geiger T, Alkan S, et al. Interferon alpha increases the frequency of interferon gamma⁃producing human CD4+ T cells［J］. J Exp Med, 1993,178（5）:1655⁃1663. doi: 10. 1084/jem.178.5.1655.
［28］	Palmer KJ, Harries M, Gore ME, et al. Interferon⁃alpha （IFN⁃alpha） stimulates anti⁃melanoma cytotoxic T lymphocyte （CTL） generation in mixed lymphocyte tumour cultures （MLTC）［J］. Clin Exp Immunol, 2000,119（3）:412⁃418. doi: 10.1046/j.1365⁃2249.2000.01159.x.
［29］	Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage ⅢB melanoma with high⁃dose interferon alfa⁃2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses［J］. J Clin Oncol, 2006,24（19）:3164⁃3171. doi: 10.1200/JCO.2005.05.2498.
［30］	Ilander M, Kreutzman A, Rohon P, et al. Enlarged memory T⁃cell pool and enhanced Th1⁃type responses in chronic myeloid leukemia patients who have successfully discontinued IFN⁃α monotherapy［J/OL］. PLoS One, 2014,9（1）:e87794. doi: 10.1371/ journal.pone.0087794.
［31］	Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon⁃alpha2b［J］. Clin Cancer Res, 2007,13（8）:2422⁃2428. doi: 10.1158/1078⁃0432.CCR⁃06⁃1805.
［32］	Novikov A, Cardone M, Thompson R, et al. Mycobacterium tuberculosis triggers host typeⅠIFN signaling to regulate IL⁃1β production in human macrophages［J］. J Immunol, 2011,187（5）:2540⁃2547. doi: 10.4049/jimmunol.1100926.
［33］	Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha⁃interferons: 40th anniversary of the discovery of interferons［J］. Cancer Res, 1998,58（12）:2489⁃2499.
［34］	Walter MR. Three⁃dimensional models of interferon⁃alpha subtypes IFN⁃con1, IFN⁃alpha8, andIFN⁃alpha1 derived from the crystal structure of IFN⁃alpha2b［J］. Semin Oncol, 1997,24（3 Suppl 9）:S9⁃52⁃S9⁃62.
［35］	Pestka S, Krause CD, Walter MR. Interferons, interferon⁃like cytokines, and their receptors［J］. Immunol Rev, 2004,202:8⁃32. doi: 10.1111/j.0105⁃2896.2004.00204.x.
［36］	Weck PK, Apperson S, May L, et al. Comparison of the antiviral activities of various cloned human interferon⁃alpha subtypes in mammalian cell cultures［J］. J Gen Virol, 1981,57（Pt 1）:233⁃237. doi: 10.1099/0022⁃1317⁃57⁃1⁃233.
［37］	Ortaldo JR, Mason A, Rehberg E, et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells［J］. J Biol Chem, 1983,258（24）:15011⁃15015.
［38］	Masci P, Olencki T, Wood L, et al. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon⁃alpha1b: a second member of the interferon⁃alpha family［J］. Clin Pharmacol Ther, 2007,81（3）:354⁃361. doi: 10.1038/sj.clpt.6100081.
［39］	冯晨, 童梅, 林福玉, 等. 干扰素α1b对黑色素瘤细胞A375增殖、迁移和凋亡的影响［J］. 现代生物医学进展,2018,18（3）:453⁃457. doi: 10.13241/j.cnki.pmb.2018.03.011.
［40］	Liu Y, Ma J, Yang Y, et al. Impact of interferon⁃alpha1b （IFN⁃α1b） on antitumor immune response: an interpretation of the promising therapeutic effect of IFN⁃alpha1b on melanoma［J］. Med Sci Monit, 2020,26:e922790. doi: 10.12659/MSM.922790.
［41］	Indraccolo S, Gola E, Rosato A, et al. Differential effects of angiostatin, endostatin and interferon⁃alpha1 gene transfer on in vivo growth of human breast cancer cells［J］. Gene Ther, 2002,9（13）:867⁃878. doi: 10.1038/sj.gt.3301703.
［42］	De Boüard S, Guillamo JS, Christov C, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon⁃alpha, angiostatin, or endostatin［J］. Hum Gene Ther, 2003,14（9）:883⁃895. doi: 10. 1089/104303403765701178.
［43］	赵艳红. 361例黑素瘤回顾性临床分析［D］. 西安: 第四军医大学, 2018.
［44］	孙薇, 乔逸, 郭丽, 等. 小儿注射重组人干扰素α1b治疗病毒性肺炎的耐受性及安全性［J］. 中国新药杂志, 2011,20（23）:2340⁃2344.
［45］	申昆玲, 张国成, 尚云晓, 等. 重组人干扰素⁃α1b在儿科的临床应用专家共识［J］. 中华实用儿科临床杂志, 2015,30（16）:1214⁃1219. doi: 10.3760/cma.j.issn.2095⁃428X.2015.16.006.
［46］	Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute′s patient⁃reported outcomes version of the common terminology criteria for adverse events （PRO⁃CTCAE）［J］. JAMA Oncol, 2015,1（8）:1051⁃1059. doi: 10.1001/jamaoncol.2015.2639.
［47］	Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy⁃related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw, 2022,20（4）:387⁃405. doi: 10.6004/jnccn.2022.0020.
［48］	Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients［J］. J Clin Oncol, 1998,16（7）:2522⁃2527. doi: 10.1200/JCO.1998.16.7.2522.
［49］	Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment［J］. J Neuropsychiatry Clin Neurosci, 1995,7（3）:347⁃350. doi: 10.1176/jnp.7.3.347.

[1]	Chinese Society of Dermatology, China Dermatologist Association, Chinese Association of Integrative Medicine Board of Dermatovenereology. Expert consensus on the clinical application of chemical peeling in China （2024 public version） [J]. Chinese Journal of Dermatology, 2024, 0(5): 20230620-e20230620.
[2]	China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.
[3]	Mycobacteriosis Research Group, China " Belt and Road " Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the diagnosis and treatment of cutaneous nontuberculous mycobacterial diseases in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 109-118.
[4]	Dong Dong, Liu Tianyi. Cell metabolism and metastasis of cutaneous malignant melanoma [J]. Chinese Journal of Dermatology, 2023, 56(9): 878-881.
[5]	Chen Fangqi, Liang Yan, Wu Ting, Huang Changzheng. Associations between m6A RNA methylation and cutaneous melanoma [J]. Chinese Journal of Dermatology, 2023, 56(9): 889-892.
[6]	Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786.
[7]	China Dermatologist Association. Guidance on application of moisturizers and emollients: an expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(8): 711-717.
[8]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[9]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[10]	Li Jiaqi, Ye Feng, Ju Qiang. Symbiotic homeostasis of Staphylococcus epidermidis is associated with common skin disorders [J]. Chinese Journal of Dermatology, 2023, 56(5): 459-462.
[11]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[12]	Zhang Congcong, Chen Hao. Spitzoid melanocytic tumors [J]. Chinese Journal of Dermatology, 2023, 56(5): 463-467.
[13]	Chen Yi, Song Xiuzu. Role of transient receptor potential channels in melanocytes and their related diseases [J]. Chinese Journal of Dermatology, 2023, 56(4): 376-379.
[14]	Yang Yongting, Li Tingting, Kang Xiaojing. Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2023, 56(3): 278-283.
[15]	Wang Yuanli, Liu Ling, Sun Zhongbin, Li Kai. Analysis of 141 cases clinically misdiagnosed as melanoma [J]. Chinese Journal of Dermatology, 2023, 56(3): 244-246.

Expert consensus on human interferon α1b for the treatment of melanoma （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［49］

Related Articles 15

Metrics

Comments

Recommended 10